Vaxcyte (PCVX) Cash from Operations (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash from Operations data on file, last reported at 280625000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 68.77% year-over-year to 280625000.0 in Q1 2026; TTM through Mar 2026 was 769928000.0, a 67.46% decrease from a year earlier, with the FY2025 full-year figure at 655577000.0, down 44.84% from the prior year.
• Cash from Operations for Q1 2026 stood at 280625000.0, down from 224832000.0 in the prior quarter.
• Over the last five years, Cash from Operations for PCVX reached as high as 27702000.0 in Q1 2022 and fell as low as 280625000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 109189176.47 across 5 years, with a median of 111401000.0 in 2024.
• On a YoY basis, Cash from Operations climbed as much as 13.52% in 2024 and fell as far as 233.66% in 2024.
• Year by year, Cash from Operations stood at 65221000.0 in 2022, then sank by 97.5% to 128810000.0 in 2023, then gained by 13.52% to 111401000.0 in 2024, then tumbled by 101.82% to 224832000.0 in 2025, then decreased by 24.82% to 280625000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 280625000.0 in Q1 2026, 224832000.0 in Q4 2025, and 143305000.0 in Q3 2025.